Galera Therapeutics Inc
OTC:GRTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Galera Therapeutics Inc
OTC:GRTX
|
US |
|
Ji Yao Holding Group Co Ltd
SZSE:300108
|
CN |
|
S
|
Sanghvi Movers Ltd
NSE:SANGHVIMOV
|
IN |
|
Lingbao Gold Group Company Ltd
HKEX:3330
|
CN |
|
E
|
Essence Information Technology Co Ltd
SSE:688555
|
CN |
|
I
|
InfoVision Optoelectronics Kunshan Co Ltd
SSE:688055
|
CN |
|
P
|
Polygiene Group AB
STO:POLYG
|
SE |
|
S
|
SGA Co Ltd
KOSDAQ:049470
|
KR |
|
Net Insight AB
STO:NETI B
|
SE |
|
J
|
JIANGSU LOPAL TECH Co Ltd
SSE:603906
|
CN |
|
I
|
i-CONTROL Holdings Ltd
HKEX:1402
|
HK |
|
E
|
Ecovacs Robotics Co Ltd
SSE:603486
|
CN |
|
Inner Mongolia Dazhong Mining Co Ltd
SZSE:001203
|
CN |
Galera Therapeutics Inc
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Malvern, Pennsylvania and currently employs 30 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutics to transform radiotherapy in cancer. The firm's lead product candidate, avasopasem manganese (GC4419), is a potent and selective small molecule dismutase mimetic, which is developed for the reduction of severe oral mucositis (SOM). The company is also developing a second dismutase mimetic product candidate, GC4711, to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). The company is evaluating GC4419 in a Phase III registrational trial (ROMAN trial) to reduce the incidence and severity of SOM induced by radiotherapy in patients with head and neck cancer (HNC), its lead indication. The firm is also evaluating GC4711 in combination with SBRT in a Phase I/II safety and anti-cancer efficacy trial in non-small cell lung cancer and a Phase IIb trial of GC4711 in combination with SBRT in patients with pancreatic cancer.
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Malvern, Pennsylvania and currently employs 30 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutics to transform radiotherapy in cancer. The firm's lead product candidate, avasopasem manganese (GC4419), is a potent and selective small molecule dismutase mimetic, which is developed for the reduction of severe oral mucositis (SOM). The company is also developing a second dismutase mimetic product candidate, GC4711, to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). The company is evaluating GC4419 in a Phase III registrational trial (ROMAN trial) to reduce the incidence and severity of SOM induced by radiotherapy in patients with head and neck cancer (HNC), its lead indication. The firm is also evaluating GC4711 in combination with SBRT in a Phase I/II safety and anti-cancer efficacy trial in non-small cell lung cancer and a Phase IIb trial of GC4711 in combination with SBRT in patients with pancreatic cancer.
